Status:
COMPLETED
Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome
Lead Sponsor:
Pavol Jozef Safarik University
Conditions:
Obstructive Sleep Apnea
Metabolic Syndrome
Eligibility:
All Genders
35-75 years
Phase:
NA
Brief Summary
The increased risk of atherosclerotic morbidity and mortality in patients with obstructive sleep apnea (OSA) has been linked to arterial hypertension, insulin resistance, systemic inflammation, and ox...
Detailed Description
Patients with obstructive sleep apnea (OSA) are at increased risk of atherosclerotic morbidity and mortality.OSA is associated with the development and/or worsening of arterial hypertension, a traditi...
Eligibility Criteria
Inclusion
- severe OSA (more than 30 obstructive apneas or hypopneas per hour of sleep and excessive daytime sleepiness)
- metabolic syndrome
Exclusion
- endocrine or metabolic disorders other than metabolic syndrome
- history of myocardial infarction, angina or stroke
- inflammatory or other chronic disease
- respiratory disorder other than OSA
- neurological lesions
- regular use of sedative medication or alcohol
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00635674
Start Date
February 1 2007
End Date
February 1 2008
Last Update
March 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Faculty, PJ Safarik University
Košice, Slovakia, Slovakia, 041 90